EXELIXIS, INC. (EXEL)

↓ Download CSV

CIK 0000939767 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Jan 1

In fiscal 2026, EXELIXIS, INC. reported revenue of $2.32B, up 7.0% from the prior year. The company was profitable, with a net margin of 33.7%. It held $2.84B in total assets against $683.10M in total liabilities.

Key ratios (FY2026)

37.6%
Operating margin
33.7%
Net margin
36.2%
Return on equity
+7.0%
Revenue growth (YoY)
Metric (FY)2026202520232022202120202018201720162015
Revenue$2.32B$2.17B$1.83B$1.61B$1.43B$967.77M$853.83M$452.48M$191.45M
Cost of Revenue$83.70M$76.22M$72.55M$57.91M$52.87M$33.10M$26.35M$15.07M$6.55M
Operating Income$872.19M$604.62M$170.88M$201.48M$286.67M$369.47M$438.86M$165.91M-$28.12M-$121.42M
Net Income$782.57M$521.27M$207.76M$182.28M$231.06M$321.01M$690.07M$154.23M-$70.22M-$161.74M
EPS (Diluted)$2.78$1.76$0.65$0.56$0.72$1.02$2.21$0.49$-0.28
Total Assets$2.84B$2.95B$2.94B$3.07B$2.62B$1.89B$1.42B$655.29M$597.54M$332.34M
Total Liabilities$683.10M$703.49M$678.45M$583.06M$405.62M$199.70M$134.83M$370.33M$508.22M$473.15M
Shareholders' Equity$2.16B$2.24B$2.26B$2.49B$2.21B$1.69B$1.29B$284.96M$89.32M
Cash & Equivalents$482.49M$217.37M$262.99M$501.19M$647.17M$266.50M$314.77M$183.16M$151.69M$141.63M
Operating Cash Flow$884.27M$699.97M$333.32M$362.61M$400.80M$526.96M$415.72M$165.61M$206.30M-$141.59M
Capital Expenditures$8.43M$28.43M$40.47M$27.71M$54.23M$12.83M$33.30M$21.14M$1.70M$447.0K
Shares Outstanding262.48M281.73M302.79M323.95M318.84M304.83M299.88M296.21M289.92M227.96M